Foundation Medicine, based in MA, Cambridge, has announced the commercial launch of FoundationACT (Assay for Circulating Tumor DNA), a blood-based genomic profiling assay for cancer patients who are not candidates for a tissue-based biopsy. The company claims that it has overcome many of the clinical limitations of other liquid biopsy tests and allows the company to be the "go-to resource for a complete, end-to-end offering of comprehensive molecular information solutions."
Foundation Medicine, based in Cambridge, MA, has announced the commercial launch of FoundationACT (Assay for Circulating Tumor DNA), a blood-based genomic profiling assay for cancer patients who are not candidates for a tissue-based biopsy. The company claims that it has overcome many of the clinical limitations of other liquid biopsy tests and allows the company to be the "go-to resource for a complete, end-to-end offering of comprehensive molecular information solutions."